Holen Sie sich die Stockscreener-App
38.79
1.70%
0.65
Handel nachbörslich:
38.57
-0.22
-0.57%
Schlusskurs vom Vortag:
$38.14
Offen:
$38.48
24-Stunden-Volumen:
1.05M
Relative Volume:
0.55
Marktkapitalisierung:
$7.96B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-505.61M
KGV:
-14.01
EPS:
-2.7697
Netto-Cashflow:
$-407.32M
1W Leistung:
+1.44%
1M Leistung:
+25.45%
6M Leistung:
+49.71%
1J Leistung:
+130.76%
1-Tages-Spanne:
$37.75
$38.85
1-Wochen-Bereich:
$37.51
$39.28
52-Wochen-Spanne:
$14.32
$39.28
Immunovant Inc Stock (IMVT) Company Profile
Firmenname
Immunovant Inc
Sektor
Branche
Telefon
917-410-3120
Adresse
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
38.79 | 7.91B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-20 | Eingeleitet | Bernstein | Mkt Perform |
| 2026-01-06 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Eingeleitet | Truist | Hold |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-03-03 | Eingeleitet | Jefferies | Hold |
| 2025-01-03 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-10-09 | Bestätigt | Oppenheimer | Outperform |
| 2024-03-28 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-13 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | JP Morgan | Overweight |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-13 | Hochstufung | UBS | Neutral → Buy |
| 2023-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Eingeleitet | BofA Securities | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Stifel | Buy |
| 2023-02-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-08-03 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-01 | Herabstufung | Stifel | Buy → Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-12 | Eingeleitet | Guggenheim | Buy |
| 2020-10-08 | Eingeleitet | Stifel | Buy |
| 2020-10-02 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-24 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Immunovant Inc Aktie (IMVT) Neueste Nachrichten
Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing - Moomoo
Immunovant COO Melanie Gloria sells $678k in company stock By Investing.com - Investing.com India
Form 144 IMMUNOVANT For: 26 June By Investing.com - Investing.com South Africa
Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I - GuruFocus
Form 4 Immunovant Inc For: 26 June By Investing.com - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (IMVT) Movement - Stock Traders Daily
Immunovant CTO Jay Stout sells $1.53m in company stock By Investing.com - Investing.com Australia
Immunovant CFO Tiago Girao sells $384,600 in company stock By Investing.com - Investing.com Australia
Immunovant chief legal officer sells $682,886 in stock - Investing.com
Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average - Stock Titan
Immunovant chief legal officer sells $682,886 in stock By Investing.com - Investing.com South Africa
Immunovant director Atul Pande sells $57,015 in stock By Investing.com - Investing.com Canada
Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake - Stock Titan
Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades - Stock Titan
Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise - Stock Titan
Immunovant (IMVT) director sells 1,500 shares after option exercise - Stock Titan
Insider Sale: President & Immunovant CEO of $ROIV Sells 46,234 Shares - Quiver Quantitative
IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header - Stock Titan
IMVT (NASDAQ: IMVT) files Form 144 for 17,824-share sale after option exercise - Stock Titan
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant Inc Actuals & Estimates (NASDAQ:IMVT) - TradingView
Price to book forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
Price to sales forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
Enterprise value to EBITDA forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
IMVT Forecast — Price Target — Prediction for 2027 - TradingView
Immunovant (IMVT) up 3.6% since last earnings report: Can it continue? - MSN
Immunovant (IMVT) CLO mandated share sale to cover RSU tax withholding - Stock Titan
Immunovant stock hits 52-week high at 36.39 USD By Investing.com - Investing.com Australia
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Immunovant stock hits 52-week high at 36.39 USD - Investing.com
Immunovant Stockweekly view after recent volatility - Ad-hoc-news.de
Immunovant stock gains 12.4% in a month: What's driving it? - MSN
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunovant Inc (IMVT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunovant Inc (IMVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunovant Inc (IMVT) Institutional Confidence - TradingKey
Immunovant Inc (IMVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan - Stock Titan
Discipline and Rules-Based Execution in IMVT Response - Stock Traders Daily
IMVT (NASDAQ: IMVT) files Form 144 reporting 6,000-share option exercise sale - Stock Titan
Immunovant Q4 earnings call highlights - MSN
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - The Globe and Mail
Finanzdaten der Immunovant Inc-Aktie (IMVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunovant Inc-Aktie (IMVT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Jun 26 '26 |
Sale |
38.31 |
40,000 |
1,532,309 |
211,685 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Option Exercise |
15.20 |
17,824 |
270,925 |
198,421 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Sale |
38.31 |
17,824 |
682,887 |
180,597 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Option Exercise |
15.90 |
10,000 |
159,000 |
257,596 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Sale |
38.46 |
10,000 |
384,600 |
247,596 |
| Pande Atul | Director |
Jun 26 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jun 26 '26 |
Sale |
38.01 |
1,500 |
57,015 |
116,731 |
3.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):